ASP0892 / Astellas, HLB Bio Group - LARVOL DELTA

Safety and immunopharmacology of ASP0892 in adults or adolescents with peanut allergy: two randomized trials. (PubMed, Allergy) - P1 | "In two phase 1 studies, ASP0892 was well tolerated with modest but not clinically relevant changes in immune responses."

Journal • Allergy • Dermatology • Food Hypersensitivity • Immunology • Pruritus

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine (clinicaltrials.gov) - P1; N=20; Completed; Sponsor: Astellas Pharma Global Development, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion • Allergy • Food Hypersensitivity • Immunology

[VIRTUAL] New treatments in food allergies (WAC 2020) - "Allergen-specific approaches -Epicutaneous immunotherapy-Sublingual immunotherapy-Subcutaneous immunotherapy with inactivated allergens -Recombinant protein vaccine (EMP-123)-Synthetic peptide vaccine (PVX-108)-DNA- LAMP vaccine (ASP0892)-High-affinity mAb specific for food allergens, e.g. Ara h 2. Among them, -Anti IgE (Omalizumab) alongside OIT-Omalizumab instead of OIT-Etokimab, directed against IL-33, a mediator necessary for sensitization to food allergens and allergic responses -Dupilumab, an antiIL-4/anti-IL-13 receptor alpha antibody already approved for the treatment of asthma and atopic dermatitis, alongside OIT. -Dupilumab alone -Anti-IL-5 antibodies mepolizimab and reslizumab, specifically in EoE."

Allergy • Asthma • Atopic Dermatitis • Dermatitis • Dermatology • Food Hypersensitivity • Immunology • Respiratory Diseases • IL13 • IL5

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: Astellas Pharma Global Development, Inc.; Active, not recruiting ➔ Recruiting

Enrollment open • Allergy • Food Hypersensitivity • Immunology

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine (clinicaltrials.gov) - P1; N=20; Active, not recruiting; Sponsor: Astellas Pharma Global Development, Inc.; Trial completion date: Dec 2020 ➔ Apr 2021; Trial primary completion date: Dec 2020 ➔ Apr 2021

Clinical • Trial completion date • Trial primary completion date • Allergy • Food Hypersensitivity • Immunology

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine (clinicaltrials.gov) - P1; N=20; Active, not recruiting; Sponsor: Astellas Pharma Global Development, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: Astellas Pharma Global Development, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine (clinicaltrials.gov) - P1; N=30; Completed; Sponsor: Astellas Pharma Global Development, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion